Literature DB >> 8557377

Resistance to Cryptococcus neoformans is associated with an inflammatory response to Toxoplasma gondii in the central nervous system of mice.

K M Aguirre1, P C Sayles, G W Gibson, L L Johnson.   

Abstract

We have studied the resistance of Toxoplasma gondii-infected mice to subsequent infection with Cryptococcus neoformans. Mice infected with the moderately virulent ME49 strain of T. gondii are resistant to proliferation of yeast cells in their brains after intravenous inoculation of the serotype A C. neoformans strain 184. The resistance serves to limit proliferation of yeast cells that colonize the brain. Maximal levels of resistance correlate not with maximal systemic specific anti-Toxoplasma resistance but rather with high levels of inflammatory response, presumably to parasites released from cysts in the brain. Resistance is localized, as mice infected with ME49 show only limited resistance in their lungs after intratracheal instillation of yeast cells, but there is substantial protection against development of cerebral cryptococcosis.

Entities:  

Mesh:

Year:  1996        PMID: 8557377      PMCID: PMC173730          DOI: 10.1128/iai.64.1.77-82.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  Tissue cyst rupture in mice chronically infected with Toxoplasma gondii. An immunocytochemical and ultrastructural study.

Authors:  D J Ferguson; W M Hutchison; E Pettersen
Journal:  Parasitol Res       Date:  1989       Impact factor: 2.289

2.  Early kinetics of Toxoplasma gondii infection in mice infected orally with cysts of an avirulent strain.

Authors:  M H Sumyuen; Y J Garin; F Derouin
Journal:  J Parasitol       Date:  1995-04       Impact factor: 1.276

3.  A protective role for endogenous tumor necrosis factor in Toxoplasma gondii infection.

Authors:  L L Johnson
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

4.  Toxoplasma gondii: effect of sublethal irradiation on host resistance in mice.

Authors:  L L Johnson; G W Gibson; P C Sayles
Journal:  Exp Parasitol       Date:  1995-09       Impact factor: 2.011

5.  Persistence of initial infection in recurrent Cryptococcus neoformans meningitis.

Authors:  E D Spitzer; S G Spitzer; L F Freundlich; A Casadevall
Journal:  Lancet       Date:  1993-03-06       Impact factor: 79.321

6.  Toxoplasma gondii: blood and tissue kinetics during acute and chronic infections in mice.

Authors:  F Derouin; Y J Garin
Journal:  Exp Parasitol       Date:  1991-11       Impact factor: 2.011

7.  Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice.

Authors:  K Aguirre; E A Havell; G W Gibson; L L Johnson
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

8.  Leishmania major infection in BALB/c mice: protection or exacerbation by treatment with different doses of BCG.

Authors:  M M Stefani; I Müller; J Louis
Journal:  Res Immunol       Date:  1993-05

9.  Cyst rupture as a pathogenic mechanism of toxoplasmic encephalitis.

Authors:  J K Frenkel; A Escajadillo
Journal:  Am J Trop Med Hyg       Date:  1987-05       Impact factor: 2.345

10.  Toxoplasmosis in nude mice.

Authors:  R E Lindberg; J K Frenkel
Journal:  J Parasitol       Date:  1977-04       Impact factor: 1.276

View more
  3 in total

1.  Antigen-induced protective and nonprotective cell-mediated immune components against Cryptococcus neoformans.

Authors:  J W Murphy; F Schafer; A Casadevall; A Adesina
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

2.  A role for B cells in resistance to Cryptococcus neoformans in mice.

Authors:  K M Aguirre; L L Johnson
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

3.  Decreased resistance to primary intravenous Cryptococcus neoformans infection in aged mice despite adequate resistance to intravenous rechallenge.

Authors:  K M Aguirre; G W Gibson; L L Johnson
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.